Gliomas have highly variable clinical outcomes that are not adequately predicted on the basis of histologic class nor genetic markers. We performed a comprehensive analysis that integrated multi-omics datasets to elucidate factors influencing glioma prognosis. We detected 17 grade-related genes different in expression between LGG and GBM cohorts. By combining multi-layer information including genetic markers, DNA methylation and gene expression, we constructed two gene networks of relations from the grade-related genes. From the networks, we identified 178 prognostic genes whose activity states, in terms of DNA methylation and gene expression level, are relevant to prognostic outcomes of gliomas, with low activity associated with better outcomes. The efficacy of these 178 genes’ activity states as prognostic factors beyond genetic markers, i.e. IDH1 or PTEN gene mutations, was validated externally. Among the 178 prognostic genes, we validated roles in gliomas for 121 genes from previous literature, and more importantly, we identified 67 novel candidate genes for glioma research. Expression of these 178 genes was particularly pronounced during fetal development in various brain regions. Our findings provide clues for understanding glioma prognosis and highlight some novel glioma-associated genes that warrant further investigation.
Modifiers significantly impact disease phenotypes by modulating the effects of disease-causing variants, resulting in varying disease manifestations among individuals. However, identifying genetic interactions between modifier and disease-causing variants is challenging. We developed MDVarP, an ensemble model comprising 1000 random forest predictors, to identify modifier ~ disease-causing variant combinations. MDVarP achieves high accuracy and precision, as verified using an independent dataset with published evidence of genetic interactions. We identified 25 novel modifier ~ disease-causing variant combinations and obtained supporting evidence for these associations. MDVarP outputs a class label ("Associated-pair" or "Nonrelevant-pair") and two prediction scores indicating the probability of a true association. MDVarP prioritizes variant pairs associated with phenotypic modulations, enabling more effective mapping of functional contributions from disease-causing and modifier variants. This framework interprets genetic interactions underlying phenotypic variations in human diseases, with potential applications in personalized medicine and disease prevention.
Studies have reported diverse functions of immune cells in response against the transplanted kidney, highlighting their significant roles in immunosuppressive response. Peripheral blood analyses showed differences in immune cell composition between kidney transplant recipients and healthy donors, however, the differences in peripheral blood immune landscape between patients with different rejection types and treatment phases remain unclear. Here, we present a single-cell RNA sequencing (scRNA-seq) dataset of peripheral blood cells derived from five participants after kidney transplantation. The dataset comprises 98,595 quality-control passed cells along with clinical metadata, enabling a comparative analysis of immune cell populations before and after immunosuppression treatment as well as between different rejection types. We preliminarily identified major cell types including immune and non-immune cells, and further annotated the immune cell subsets. This transcriptomic data will serve as a resource to explore new cellular biomarkers and microenvironmental changes in peripheral blood of kidney recipients with different reaction types, and to deepen our insights into the role of immunosuppression treatment on graft rejection.